AdaptHealth Reports Wider Q1 Loss, Negative Free Cash Flow Amid Debt Refinancing and Regulatory Headwinds
AHCO sits 48% above its 52-week low of $7.95 on elevated volume (3.2× avg).
Summary
AdaptHealth Corp. reported a significantly wider net loss and negative free cash flow in Q1 2026, despite revenue growth, while also announcing a major debt refinancing and facing new regulatory challenges.
Key Events · Earnings and Guidance · AHCO
-
Wider Net Loss and Negative Free Cash Flow
Net loss attributable to AdaptHealth Corp. increased to $16.040 million for Q1 2026, compared to $7.207 million in Q1 2025. The company also reported a significant negative free cash flow of $27.490 million for the quarter, a substantial increase from negative $0.058 million in the prior year.
-
Major Debt Refinancing Completed
Subsequent to the quarter end, on April 10, 2026, AdaptHealth refinanced its debt, entering into a new credit agreement consisting of a $325 million term loan, a $325 million delayed draw term loan, and a $450 million revolving credit facility. $100 million was borrowed under the new revolver at closing, used in part to repay existing debt.
-
New Regulatory Moratorium Poses Risk
The Centers for Medicare & Medicaid Services (CMS) imposed a 6-month nationwide temporary moratorium on Medicare enrollment for certain DMEPOS 'medical supply company' supplier types, which could limit the company's ability to expand or pursue acquisitions.
-
Legal Settlements Reached
The company reached an agreement in principle to settle a class action lawsuit for $35 million ($1 million paid by the company, $34 million from insurance carriers) and another class action for $14.5 million. Agreements in principle were also reached for several shareholder derivative complaints.
Analysis · AHCO · Industrial Applications And Services
AdaptHealth's first-quarter results reveal a concerning trend of declining profitability, with a significantly wider net loss and a substantial negative free cash flow, despite a modest increase in revenue. The company's working capital also shifted to a negative position. While the subsequent debt refinancing provides crucial liquidity and extends maturities, it highlights the company's ongoing need for capital amidst operational challenges. The new regulatory moratorium from CMS introduces a material risk to the company's growth strategy, particularly regarding new locations and acquisitions. The ongoing legal settlements, though partially covered by insurance, represent significant liabilities. Investors should closely monitor the company's ability to improve profitability, manage its cash flow, and navigate the new regulatory environment.
At the time of this filing, AHCO was trading at $11.75 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $7.95 to $13.43. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.